Fulvestrant improves survival over anastrozole for patients with advanced breast cancer

Share :
Published: 12 Dec 2014
Views: 3093
Prof John Robertson - Royal Derby Hospital, Derby, UK

At a press conference at SABCS 2014, Prof Robertson discusses the results of the phase II FIRST trial, which compared overall survival with fulvestrant versus anastrozole as first-line treatment for patients with advanced hormone receptor-positive breast cancer:

Those patients who took fulvestrant lived longer than those who took anastrozole.

Read the news story or watch the interview here.